Información de la revista
Vol. 101. Núm. 5.
Páginas 421-427 (junio - julio 2010)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 101. Núm. 5.
Páginas 421-427 (junio - julio 2010)
Original article
Acceso a texto completo
Clinical Outcomes in Patients With Psoriasis Following Discontinuation of Efalizumab Due to Suspension of Marketing Authorization
Evolución clínica de los pacientes psoriásicos tratados con efalizumab al suspender el fármaco
Visitas
5733
O. Baniandrés
Autor para correspondencia
ofelia_baniandres@yahoo.es

Corresponding author.
, A. Pulido, C. Silvente, R. Suárez, P. Lázaro
Servicio de Dermatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Este artículo ha recibido
Información del artículo
Abstract
Introduction

In February 2009, the European Medicines Agency suspended the marketing authorization for efalizumab after 3 confirmed cases of progressive multifocal leukoencephalopathy were reported. To assess the consequences of this decision, we performed a prospective follow-up study of patients in our department who were being treated with efalizumab at the time and compared clinical outcomes with data from the literature.

Patients and methods

Thirty-two patients (28 with plaque psoriasis and 4 with palmoplantar psoriasis) were enrolled between February and March 2009. We recorded psoriasis area and severity index (PASI) scores at the moment of efalizumab discontinuation, at 6 weeks post-discontinuation, and at 3-monthly intervals thereafter. PASI scores prior to treatment with efalizumab were also noted. For patients who experienced rebounds with generalized psoriasis, we noted the time that had elapsed since efalizumab discontinuation and the treatment they were receiving.

Results

Even though 92.8% of the patients were considered good responders (>75% reduction in PASI score), 25% of the group (8/32) experienced rebound and 15.7% (5/32) experienced relapse. The percentage of patients in whom rebound was observed on transition therapy was 18% (2/11) for cyclosporin, 50% (1/2) for methotrexate, 50% (1/2) for adalimumab, 50% (1/2) for etanercept, and 27% (3/11) for topical treatment.

Conclusions

We observed a very high rate of rebound and generalized inflammation in patients whose disease had previously been well controlled for several years.

Keywords:
Efalizumab
Progressive multifocal leukoencephalopathy
Psoriasis
Rebound
Relapse
Treatment discontinuation
Resumen
Introducción

En febrero de 2009 la Agencia Europea de Evaluación de Medicamentos (EMEA) suspendió la comercialización de efalizumab por la notificación de tres casos confirmados de leucoencefalopatía multifocal progresiva (LMP). Nos planteamos realizar un estudio prospectivo de seguimiento de los pacientes tratados en nuestro Servicio con efalizumab en el momento de la suspensión y comparar la evolución con las perspectivas publicadas en la literatura.

Pacientes y métodos

Se incluyeron 32 pacientes (28 con psoriasis en placas y 4 con psoriasis palmoplantar) entre febrero y marzo de 2009. Se recogió el Psoriasis Area and Severity Index (PASI) previo al comienzo del tratamiento con efalizumab, en el momento de la suspensión, a las 6 semanas y posteriormente cada tres meses. En el caso de los pacientes que presentaron brotes generalizados se recogió el tiempo transcurrido desde la suspensión y el manejo terapéutico que se realizó.

Resultados

A pesar de que el 92,8% de los pacientes correspondían a buenos respondedores (mejoría PASI > 75), presentaron rebote un 25% de los sujetos (8/32) y recaídas un 15,7% (5/32). Con respecto a la terapia de transición presentaron rebote un 18% de los pacientes (2/11) con ciclosporina, un 50% (1/2) con metotrexato, un 50% (1/2) con adalimumab, un 50% (1/2) con etanercept y un 27% (3/11) de los que recibieron tratamiento tópico.

Conclusiones

Hemos encontrado un porcentaje muy alto de rebote y formas generalizadas inflamatorias en pacientes que habían conseguido un buen control de la psoriasis durante varios años.

Palabras clave:
Efalizumab
Leucoencefalopatía multifocal progresiva
Psoriasis
Rebote
Recaída
Suspensión
El Texto completo está disponible en PDF
References
[1]
M. Lebwohl, S. Tyring, T. Hamilton, D. Toth, S. Glazer, N.H. Tawfik, et al.
A novel targeted T-cell modulator, efalizumab, for plaque psoriasis.
N Engl J Med, 349 (2003), pp. 2004-2013
[2]
C.L. Leonardi, D. Toth, J.C. Cather, R.G. Langley, W. Werther, P. Compton, et al.
A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis.
Dermatology, 213 (2006), pp. 204-214
[3]
A. Menter, K. Gordon, W. Carey, T. Hamilton, S. Glazer, I. Caro, et al.
Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Arch Dermatol, 141 (2005), pp. 31-38
[4]
L. Dubertret, W. Sterry, J.D. Bos, S. Chimenti, S. Shumack, C.G. Larsen, et al.
Clinical experience acquired with efalizumab (Raptiva) (CLEAR) trial in patients with moderate to severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Br J Dermatol, 155 (2006), pp. 170-181
[5]
C. Leonardi, A. Menter, T. Hamilton, I. Caro, B. Xing, A.B. Gottlieb.
Efalizumab: Results of a 3-year continuous dosing study for the long-term control of psoriasis.
Br J Dermatol, 158 (2008), pp. 1107-1116
[6]
L. Puig, J.M. Carrascosa, E. Dauden, J.L. Sánchez-Carazo, C. Ferrándiz, M. Sánchez-Regaña, et al.
Directrices españolas basadas en la evidencia para el tratamiento de la psoriasis moderada a grave con agentes biológicos.
Actas Dermosifiliogr, 100 (2009), pp. 386-413
[7]
K.R. Carson, D. Focosi, E.O. Major, M. Petrini, E.A. Richey, D.P. West, et al.
Monoclonal antibody associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project.
Lancet Oncol, 10 (2009), pp. 816-824
[8]
E. Daudén, M.J. Oñate.
Efalizumab: ¿Un tratamiento seguro para una enfermedad crónica?.
Actas Dermosifiliogr, 99 (2008), pp. 18-28
[9]
L. Puig, E. Roé, X. García-Navarro, F. Corella, A. Alomar.
Efalizumab treatment of psoriasis vulgaris: a cohort study in outpatient clinical practice.
Clin Exp Dermatol, 34 (2009), pp. 469-475
[10]
T.F. Tsai, M.T. Liu, Y.H. Liao, D. Licu.
Clinical effectiveness and safety experience with efalizumab in the treatment of patients with moderate-to-severe plaque psoriasis in Taiwan: results of an open-label, single-arm pilot study.
J Eur Acad Dermatol Venereol, 22 (2008), pp. 345-352
[11]
W. Carey, S. Glazer, A.B. Gottlieb, M. Lebwohl, C. Leonardi, A. Menter, et al.
Relapse, rebound and psoriasis adverse events: an advisory Group report.
J Am Acad Dermatol, 54 (2006), pp. S171-S181
[12]
A. Menter, T.K. Hamilton, D.P. Toth, H.M. Leung, G. Wetherill, B. Hennessey, et al.
Transitioning patients from efalizumab to alternative psoriasis therapies: findings from an open-label, multicenter, Phase IIIb study.
Int J Dermatol, 46 (2007), pp. 637-648
[13]
K.B. Gordon, S.R. Feldman, J.Y. Koo, A. Menter, T. Rolstad, G. Krueger.
Definitions of measures of effect duration for psoriasis treatments.
Arch Dermatol, 141 (2005), pp. 82-84
[14]
R. Pugashetti, J. Koo.
Efalizumab discontinuation: A practical strategy.
J Dermatolog Treat, 20 (2009), pp. 132-136
[15]
K.A. Papp, D. Toth, L. Rosoph.
Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence.
BMC Dermatol, 26 (2006), pp. 6-9
[16]
J.M. Carrascosa.
Estrategias para optimizar el tratamiento con efalizumab.
Actas Dermosifiliogr, 99 (2008), pp. 37-50
[17]
A.M. Brunasso, C. Delfino, C. Massone.
Efalizumab rebound to sequential therapy of infliximab followed by efalizumab.
Dermatology, 218 (2009), pp. 73-74
[18]
L. Yip, S. Harrison, P. Foley.
Infliximab rescue of efalizumab withdrawal flare and psoriasis precipitated depression.
Australas J Dermatol, 49 (2008), pp. 250-251
[19]
L. Yip, S. Harrison, P. Foley.
From biologic to biologic to biologic: Lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis.
Australas J Dermatol, 49 (2008), pp. 152-155
[20]
A.M. Thielen, C. Barde, J.H. Saurat.
Infliximab- and methotrexateresistant rebound after discontinuation of efalizumab.
Br J Dermatol, 155 (2006), pp. 846-847
[21]
B. Martín, J.L. Sánchez-Carazo, A. Pérez-Ferriols, V. Oliver, V. Alegre.
Delayed generalized inflammatory psoriasis flare during efalizumab treatment.
Br J Dermatol, 161 (2009), pp. 212-213
[22]
E.N. Kop, J.E.M. Körver, D. Van Ruysevelt, E.M.G.J. De Jong, P.G. Van der Valk, P.C.M. Van de Kerkhof.
Erythroderma in two patients with psoriasis upon discontinuation of efalizumab treatment.
J Dermatolog Treat, 20 (2009), pp. 67-69
[23]
M.A. Lowes, F. Chamiam, M.V. Abello, C. Leonardi, W. Dummer, K. Papp, et al.
Eruptive papules during efalizumab (anti CD11a) therapy of psoriasis vulgaris: a case series.
BMC Dermatol, 7 (2007), pp. 2
Copyright © 2010. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Descargar PDF
Idiomas
Actas Dermo-Sifiliográficas
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?